The Combination of Phage Therapy and β-Lactam Antibiotics for the Effective Treatment of Enterococcus faecalis Infections DOI Open Access
Magdalena Moryl,

Paulina Szychowska,

Julia Dziąg

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 26(1), С. 11 - 11

Опубликована: Дек. 24, 2024

A phage–antibiotic synergy could be an alternative in urinary tract infection (UTI) therapy, as it leads to the elimination of bacteria and reduction variants resistant phages antibiotics. The aims vitro study were determine whether vB_Efa29212_2e vB_Efa29212_3e interact synergistically with selected antibiotics treatment E. faecalis infections, optimize antibiotic concentrations phage titers for most effective combinations, assess their impact on number spontaneous phages’ reproductive cycles. modified double-layer disc diffusion method, checkboard, time–kill assays, one-step growth method double agar overlay plaque assay implemented. Synergistic interactions often observed after combined action 2e or 3e β-lactam strains. beneficial effects depended bacterial strain, used. lowest minimum inhibitory concentration (MIC50) values recorded, application low 2e, high 3e. use tested agents resulted a significant had cycle phages, e.g., 50% increase burst size, 5 min latency period observed. confirmed between against growth.

Язык: Английский

Phage Therapy: A Targeted Approach to Overcoming Antibiotic Resistance DOI Creative Commons
David B. Olawade, Oluwaseun Fapohunda,

Eghosasere Egbon

и другие.

Microbial Pathogenesis, Год журнала: 2024, Номер unknown, С. 107088 - 107088

Опубликована: Окт. 1, 2024

Язык: Английский

Процитировано

15

Does Phage Therapy Need a Pan-Phage? DOI Creative Commons
Petros Bozidis,

Eleftheria Markou,

Athanasia Gouni

и другие.

Pathogens, Год журнала: 2024, Номер 13(6), С. 522 - 522

Опубликована: Июнь 20, 2024

The emergence of multidrug-resistant bacteria is undoubtedly one the most serious global health threats. One response to this threat that has been gaining momentum over past decade 'phage therapy'. According this, lytic bacteriophages are used for treatment bacterial infections, either alone or in combination with antimicrobial agents. However, ensure efficacy and broad applicability phage therapy, several challenges must be overcome. These encompass development methods strategies host range manipulation bypass resistance mechanisms developed by pathogenic bacteria, as case since advent antibiotics. As our knowledge understanding interactions between phages their hosts evolves, key issue define each application. In article, we discuss factors affect how determines classification into different categories action. For group, recent representative examples provided, together suggestions on groups can combat certain types infections. available methodologies expansion, through sequential adaptation a new pathogen genetic engineering techniques, also reviewed.

Язык: Английский

Процитировано

7

Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis DOI Open Access
Mario Cocorullo, Giovanni Stelitano, Laurent R. Chiarelli

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(15), С. 8321 - 8321

Опубликована: Июль 30, 2024

Patients with cystic fibrosis (CF) are prone to developing life-threatening lung infections a variety of pathogens that difficult eradicate, such as Burkholderia cepacia complex (Bcc), Hemophilus influenzae, Mycobacterium abscessus (Mab), Pseudomonas aeruginosa, and Staphylococcus aureus. These still remain an important issue, despite the therapy for CF having considerably improved in recent years. Moreover, prolonged exposure antibiotics combination favors development spread multi-resistant bacteria; thus, alternative strategies is crucial counter antimicrobial resistance. In this context, phage therapy, i.e., use phages, viruses specifically infect bacteria, has become promising strategy. review, we aim address current status management multidrug-resistant infections, from compassionate cases ongoing clinical trials, well challenges approach presents particular context patients.

Язык: Английский

Процитировано

4

Probing the interaction of Paenibacillus larvae bacteriophage as a biological agent to control the american foulbrood disease in honeybee DOI Creative Commons
Rasha M. El-Meihy, Eman Hassan, Soha A. Alamoudi

и другие.

Saudi Journal of Biological Sciences, Год журнала: 2024, Номер 31(6), С. 104002 - 104002

Опубликована: Апрель 25, 2024

American foulbrood (AFB) is a harmful honeybee disease primarily caused by Paenibacillus larvae. The study aims to isolate and identify the AFB causative agent P. larvae their specific phages use as new biological method for control. Eight apiaries were inspected infections. Symptoms of diseased brood comb, odd cells with soft brown decayed amongst healthy brood, identified in field demonstrated prevalence every apiary. Three isolates using traditional techniques 452-bp PCR amplicon bacterial 16SrRNA gene was compared between isolates. Additionally, strains applied examine efficiency reducing infection rate under apiary condition. reduced approximately 94.6 100 % through application phage mixture, opposed 20 85.7 when each administered individually or 78.6 88.9 antibiotic treatment implemented. Histological studies on phage-treated bee revealed some regaining normal shape, prominent nuclei microvilli. gastrointestinal tract showed longitudinal circular muscles, unlike treated abnormal destroyed tissues, shown basement membrane surrounding mid-gut epithelium. Phage exhibited promise resolving issue honeybees due ease application, comparatively lower cost, practicality beekeepers terms laboratory preparation.

Язык: Английский

Процитировано

3

Phage therapy in the management of respiratory and pulmonary infections: a systematic review DOI Creative Commons
Patience Sarkodie-Addo, Abdul-Halim Osman, Bill Clinton Aglomasa

и другие.

Therapeutic Advances in Infectious Disease, Год журнала: 2025, Номер 12

Опубликована: Янв. 1, 2025

Lower respiratory tract infections (LRTIs) pose a significant threat to global health, causing more than 2 million deaths worldwide. This menace is intensified by the alarming increase in drug resistance, which limits availability of effective antibiotics for bacterial infections. Consequently, there an urgent demand alternative therapeutic options. Phage therapy (PT) has re-emerged as promising approach and adjunct antibiotic treatment. systematic review synthesises application PT LRTIs humans, providing unified updated data on evaluation safety efficacy LRTIs. Systematic review. Following PRISMA guidelines, comprehensive search strategy was carried out (spanning January 2000 - February 2024) four databases: PubMed, Scopus, ScienceDirect Web Science retrieve published records humans only. The reference list each included study evaluated possible inclusion other relevant articles. Among 18 that fulfilled criteria, 70 patients were administered PT. Microbiologically, 71.42% (n = 50/70) improved; with either eradication pathogen or decrease load, whilst 15.71% 11/70) did not record any improvement. About 5.71% 4/70) recorded partial/incomplete improvement, 7.14% 5/70) microbiological outcomes unspecified. Clinically, up 74.29% 52/70) improved, 10.00% 7/70) showed no Another 2.86% 2/70) 12.86% 9/70) uncategorized. titres yielded positive ranged from 105 1012 PFU/mL. Studies achieved substantial phage titre at site infection frequently observed notable improvements. Regarding PT, 77.78% (N 14/18) studies adverse effects after administered, 16.66% 3/18) reported effects. Based recently originating mainly observational studies, shown considerable treatment However, lack uniform methodologies protocols across different cases management need additional clinical establish standardised pharmacokinetic elements overall protocol By doing so, we can fully unlock potential effectively managing infections, including

Язык: Английский

Процитировано

0

The Current Landscape of Phage–Antibiotic Synergistic (PAS) Interactions DOI Creative Commons

Brittany S. I. Supina,

Jonathan J. Dennis

Antibiotics, Год журнала: 2025, Номер 14(6), С. 545 - 545

Опубликована: Май 27, 2025

Background: In response to the urgent need for new antibiotics targeting high-priority MDR pathogens, bacteriophages (phages) have emerged as promising non-traditional antimicrobial agents. Phages are viruses that infect bacteria and induce cell lysis through mechanisms distinct from those of antibiotics, making them largely unaffected by most antibiotic resistance mechanisms. Importantly, phages been shown work cooperatively with an array clinically useful phage–antibiotic synergy (PAS) represents a sophisticated strategy may improve treatment outcomes. However, interactions between diverse, ranging synergistic antagonistic, understanding underlying these is crucial developing effective PAS treatments. this review, we summarize potential evolutionary molecular drive current landscape interactions. Conclusions: Towards development robust strategies, review in vitro methods assessing considerations choosing employing candidate combinations.

Язык: Английский

Процитировано

0

Current Clinical Laboratory Challenges to Widespread Adoption of Phage Therapy in the United States DOI Creative Commons

Ahnika Kline,

Ana G. Cobián-Güemes, Jennifer Yore

и другие.

Antibiotics, Год журнала: 2025, Номер 14(6), С. 553 - 553

Опубликована: Май 29, 2025

The resurgence of phage therapy in Western societies has been direct response to recent increases antimicrobial resistance (AMR) that have ravaged many societies. While as a concept around for over 100 years, it largely replaced by antibiotics due their relative ease use and predictability spectrum activity. Now become less reliable greater antibiotic microbiome disruption, once again viable promising alternative, but is not without its challenges. Much like the development antibiotics, with deployment therapeutics there will be simultaneous need diagnostics clinical laboratory. This review provides an overview current challenges widespread adoption focus on diagnostic Current barriers include lack standard methodology quality controls susceptibility testing selection, absence phage-antibiotic synergy testing, methods assay activity biofilms. Additionally, are number lab-specific administrative regulatory including pharmacokinetic (PK) pharmacodynamic (PD) assays, account changes phages after passaging, guidance what required agency approvals how broad approval apply, increased lab personnel or automation work large libraries against bacteria isolates.

Язык: Английский

Процитировано

0

Phage Therapy: An Alternative Approach to Combat Multi-drug Resistant Infections in Cystic Fibrosis DOI Open Access
Mario Cocorullo, Giovanni Stelitano, Laurent R. Chiarelli

и другие.

Опубликована: Июнь 21, 2024

In this review we aim to address the current status of phage therapy in management multidrug-resistant infections, from compassionate use cases ongoing clinical trials, as well challenges approach presents particular context CF patients.

Язык: Английский

Процитировано

2

Phage-Based Therapy in Combination with Antibiotics: A Promising Alternative against Multidrug-Resistant Gram-Negative Pathogens DOI Creative Commons
Cleo Anastassopoulou, Stefanos Ferous,

Aikaterini Petsimeri

и другие.

Pathogens, Год журнала: 2024, Номер 13(10), С. 896 - 896

Опубликована: Окт. 14, 2024

The continued rise in antimicrobial resistance poses a serious threat to public health worldwide. use of phages that can have bactericidal activity without disrupting the normal flora represents promising alternative treatment method. This practice has been successfully applied for decades, mainly Eastern Europe, and recently used as an emergency therapy compassionate care United States. Here, we provide comprehensive review pre-clinical clinical applications phage concerning three major Gram-negative pathogens:

Язык: Английский

Процитировано

2

Beyond Antibiotics: Exploring the Potential of Bacteriophages and Phage Therapy DOI Open Access
Sudhangshu Kumar Biswas,

Md. Mehedi Hasan Sumon,

Sabbir Ahmed

и другие.

PHAGE, Год журнала: 2024, Номер 5(4), С. 186 - 202

Опубликована: Окт. 24, 2024

The escalating global threat of antibiotic resistance has prompted a critical need for innovative approaches to bacterial infection treatment. In terms management, bacterial-associated disorders have reached point in the world due advent drug-resistant types bacteria. Nonetheless, continued bacteriophage research presents promising frontier battle against infections. this study, we explored effectiveness therapy antibiotic-resistant According our viewpoint, phage could replace antibiotics safety, efficacy, and specificity. Furthermore, offers versatility administering single phage, products, or modified various resistant Moreover, Phage cocktails, with their synergistic combinations, showcase holistic approach, mitigating risk expanding treatment possibilities. Similarly, synergy between phages holds promise overcoming forging path toward more effective sustainable antimicrobial strategies. review provides insights into transformative impact on current paradigms, its application methodological challenges limitations, as well scientists policymakers best areas study order combat resistance.

Язык: Английский

Процитировано

1